NIKKEI 225
37,692.04 +63.56 (+0.17%) HANG SENG
17,284.54 +83.27 (+0.48%) CRUDE OIL
83.87 +0.30 (+0.36%) GOLD FUTURES
2,340.90 -1.60 (-0.07%) DOW
38,085.80 -375.12 (-0.98%) Bitcoin GBP
51,420.78 -204.02 (-0.40%)
GC Biopharma Corp. (006280.KS)
- PR Newswire
GC Cell to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024
GC Cell, a fully integrated cell therapy pioneer has announced poster presentations from studies of its preclinical study of GL205 (GCC2005), a CD5 CAR-NK targeting malignant T-cell lymphoma, and real-world data for the anticancer immunotherapy drug 'Immuncell-LC' at the AACR Annual Meeting 2024 that will take place in San Diego, California, on April 5-10.
- PR Newswire
GC Cell and BioCentriq® Execute Process Transfer Agreement in Anticipation of the U.S. entry of Immuncell-LC Inj.
GC Cell, a fully integrated cell therapy pioneer has announced a strategic partnership with BioCentriq, a cell therapy contract development and manufacturing organization (CDMO) and US affiliate of GC Cell. This important partnership lays the foundation to bring GC Cells' proven cell-based immunotherapy, Immuncell-LC to the North American market. The execution of a Process Transfer Agreement with BioCentriq effectively lays the foundation for the U.S. launch of Immuncell-LC through utilization o
- PR Newswire
GC Biopharma Presents Updates on its LSD Treatments at the WORLDSymposium 2024
GC Biopharma (CEO, Eun-Chul Huh), a South Korean biopharmaceutical company, announced on Feb. 14th that it has presented the development updates on its LSD (Lysosomal Storage Diseases) medicines at the WORLDSymposium 2024 held on Feb. 4th-9th, 2024 in San Diego, USA.
